Immuneering (IMRX) Return on Capital Employed (2021 - 2026)

Immuneering's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 27.12% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 11075.0% year-over-year to 27.12%; the TTM figure through Mar 2026 stood at 27.12% (up 11075.0% YoY), while the FY2025 annual figure was 44.89%, up 4645.0% from the prior year.
• Return on Capital Employed was 27.12% for Q1 2026 at Immuneering, down from 26.22% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 26.03% in Q1 2022 to a low of 169.14% in Q2 2025.
• Historically, Return on Capital Employed has averaged 65.46% across 5 years, with a median of 49.31% in 2023.
• The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 8932 bps in 2025, then soared 11075 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 43.13% in 2022, then sank by 35 bps to 58.19% in 2023, then slumped by 107 bps to 120.59% in 2024, then surged by 78 bps to 26.22% in 2025, then decreased by 3 bps to 27.12% in 2026.
• The last three Return on Capital Employed figures came in at 27.12% (Q1 2026), 26.22% (Q4 2025), and 48.99% (Q3 2025), per Business Quant data.